Illumina’s NovaSeq Platform, the $100 Human Genome & Moore’s Law: is it Good Business?

At the JP Morgan Conference on Monday, Illumina took the opportunity showcase its new DNA sequencers, the NovaSeq 5000 and NovaSeq 6000, promising that by the end of the year

Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific

A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for the company throughout 2016

Thermo Fisher and Illumina Prepare for Round Two of the Next-Gen Sequencing Battle

Earlier this month Thermo Fisher Scientific announced the launch of two novel next-generation sequencing (NGS) instruments, the Ion S5 and the Ion S5 XL benchtop systems, which combine the ability

Illumina Reports Record Financial Results for Third Quarter of Fiscal Year 2014 Illumina, Inc. announced its financial results for the third quarter of 2014. Third quarter 2014 results: Revenue of